Page last updated: 2024-12-11

zoniporide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

zoniporide: inhibits sodium-hydrogen exchanger isoform-1 (NHE-1) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6433110
CHEMBL ID355862
SCHEMBL ID611159
MeSH IDM0385337

Synonyms (26)

Synonym
zoniporide [inn]
bdbm50097898
n-(5-cyclopropyl-1-quinolin-5-yl-1h-pyrazole-4-carbonyl)-guanidine
zoniporide
CHEMBL355862 ,
5-cyclopropyl-n-(diaminomethylidene)-1-quinolin-5-ylpyrazole-4-carboxamide
zoniporide [inn:ban]
unii-8841r2ujpg
n-carbamimidoyl-5-cyclopropyl-1-(quinolin-5-yl)-1h-pyrazole-4-carboxamide
8841r2ujpg ,
241800-98-6
cp-597,396
(1-(quinolin-5-yl)-5-cyclopropyl-1h-pyrazole-4-carbonyl)guanidine hydrochloride monohydrate
SCHEMBL611159
n-(5-cyclopropyl-1-quinolin-5-yl-1h-pyrazole4-carbonyl)-guanidine
GDXBRVCQGGKXJY-UHFFFAOYSA-N
[5-cyclopropyl-1-(quinolin-5-yl)-1h-pyrazole-4-carbonyl]guanidine
DTXSID0057883
NCGC00386683-01
PS-18710
Q27269884
CS-0024861
mfcd32004449
SY284545
n-carbamimidoyl-5-cyclopropyl-1-(5-quinolyl)pyrazole-4-carboxamide
F78290

Research Excerpts

Overview

Zoniporide (CP-597,396) is a potent and selective inhibitor of NHE-1. It exhibits high aqueous solubility and acceptable pharmacokinetics for intravenous administration.

ExcerptReferenceRelevance
"Zoniporide (CP-597,396) is a potent and selective inhibitor of NHE-1, which exhibits high aqueous solubility and acceptable pharmacokinetics for intravenous administration. "( Discovery of zoniporide: a potent and selective sodium-hydrogen exchanger type 1 (NHE-1) inhibitor with high aqueous solubility.
Allen, MC; Brown, JA; Buchholz, AR; Cook, ER; Day, WW; Guzman-Perez, A; Hamanaka, ES; Hill, RJ; Kennedy, SP; Knight, DR; Kowalczyk, PJ; Marala, RB; Mularski, CJ; Novomisle, WA; Ruggeri, RB; Tracey, WR; Wester, RT, 2001
)
2.12
"Zoniporide is a potent cardioprotective agent and activation of STAT3 plays a critical role in the cardioprotective action of zoniporide. "( Critical role of the STAT3 pathway in the cardioprotective efficacy of zoniporide in a model of myocardial preservation - the rat isolated working heart.
Gao, L; Hicks, M; Kwan, J; Macdonald, PS; Sun, L; Tsun, J; Watson, A, 2011
)
2.05

Pharmacokinetics

ExcerptReferenceRelevance
"The pharmacokinetic properties of drugs may be altered by kinetic deuterium isotope effects."( Deuterium isotope effects on drug pharmacokinetics. I. System-dependent effects of specific deuteration with aldehyde oxidase cleared drugs.
Clark, AJ; Gao, H; Obach, RS; Ripp, SL; Schildknegt, K; Sharma, R; Spracklin, DK; Strelevitz, TJ; Tremaine, LM; Vaz, AD, 2012
)
0.38

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (3)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Sodium/hydrogen exchanger 1Homo sapiens (human)IC50 (µMol)0.05900.00500.56013.5000AID1341120; AID1341847; AID1411094; AID143806
Sodium/hydrogen exchanger 3Rattus norvegicus (Norway rat)IC50 (µMol)500.00000.00930.60862.4000AID1341123; AID1341851; AID1411098
Sodium/hydrogen exchanger 2Homo sapiens (human)IC50 (µMol)12.00002.00004.01439.2000AID1341121; AID1341850; AID1411095; AID143808
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (42)

Processvia Protein(s)Taxonomy
monoatomic ion transportSodium/hydrogen exchanger 1Homo sapiens (human)
intracellular sodium ion homeostasisSodium/hydrogen exchanger 1Homo sapiens (human)
regulation of pHSodium/hydrogen exchanger 1Homo sapiens (human)
response to acidic pHSodium/hydrogen exchanger 1Homo sapiens (human)
positive regulation of cardiac muscle hypertrophySodium/hydrogen exchanger 1Homo sapiens (human)
regulation of cardiac muscle contraction by calcium ion signalingSodium/hydrogen exchanger 1Homo sapiens (human)
cell migrationSodium/hydrogen exchanger 1Homo sapiens (human)
maintenance of cell polaritySodium/hydrogen exchanger 1Homo sapiens (human)
positive regulation of cell growthSodium/hydrogen exchanger 1Homo sapiens (human)
cellular response to insulin stimulusSodium/hydrogen exchanger 1Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilitySodium/hydrogen exchanger 1Homo sapiens (human)
response to muscle stretchSodium/hydrogen exchanger 1Homo sapiens (human)
sodium ion export across plasma membraneSodium/hydrogen exchanger 1Homo sapiens (human)
positive regulation of apoptotic processSodium/hydrogen exchanger 1Homo sapiens (human)
negative regulation of apoptotic processSodium/hydrogen exchanger 1Homo sapiens (human)
positive regulation of action potentialSodium/hydrogen exchanger 1Homo sapiens (human)
positive regulation of transcription by RNA polymerase IISodium/hydrogen exchanger 1Homo sapiens (human)
stem cell differentiationSodium/hydrogen exchanger 1Homo sapiens (human)
protein complex oligomerizationSodium/hydrogen exchanger 1Homo sapiens (human)
regulation of intracellular pHSodium/hydrogen exchanger 1Homo sapiens (human)
regulation of stress fiber assemblySodium/hydrogen exchanger 1Homo sapiens (human)
regulation of focal adhesion assemblySodium/hydrogen exchanger 1Homo sapiens (human)
cardiac muscle cell differentiationSodium/hydrogen exchanger 1Homo sapiens (human)
cellular response to coldSodium/hydrogen exchanger 1Homo sapiens (human)
positive regulation of calcineurin-NFAT signaling cascadeSodium/hydrogen exchanger 1Homo sapiens (human)
cellular response to antibioticSodium/hydrogen exchanger 1Homo sapiens (human)
cellular response to electrical stimulusSodium/hydrogen exchanger 1Homo sapiens (human)
cellular response to mechanical stimulusSodium/hydrogen exchanger 1Homo sapiens (human)
cellular response to organic cyclic compoundSodium/hydrogen exchanger 1Homo sapiens (human)
cellular response to hypoxiaSodium/hydrogen exchanger 1Homo sapiens (human)
cellular response to acidic pHSodium/hydrogen exchanger 1Homo sapiens (human)
cellular response to epinephrine stimulusSodium/hydrogen exchanger 1Homo sapiens (human)
cardiac muscle cell contractionSodium/hydrogen exchanger 1Homo sapiens (human)
regulation of cardiac muscle cell membrane potentialSodium/hydrogen exchanger 1Homo sapiens (human)
regulation of the force of heart contraction by cardiac conductionSodium/hydrogen exchanger 1Homo sapiens (human)
sodium ion import across plasma membraneSodium/hydrogen exchanger 1Homo sapiens (human)
positive regulation of the force of heart contractionSodium/hydrogen exchanger 1Homo sapiens (human)
proton transmembrane transportSodium/hydrogen exchanger 1Homo sapiens (human)
positive regulation of calcium:sodium antiporter activitySodium/hydrogen exchanger 1Homo sapiens (human)
potassium ion transmembrane transportSodium/hydrogen exchanger 1Homo sapiens (human)
monoatomic ion transportSodium/hydrogen exchanger 2Homo sapiens (human)
protein localizationSodium/hydrogen exchanger 2Homo sapiens (human)
epithelial cell differentiationSodium/hydrogen exchanger 2Homo sapiens (human)
proton transmembrane transportSodium/hydrogen exchanger 2Homo sapiens (human)
sodium ion import across plasma membraneSodium/hydrogen exchanger 2Homo sapiens (human)
potassium ion transmembrane transportSodium/hydrogen exchanger 2Homo sapiens (human)
regulation of intracellular pHSodium/hydrogen exchanger 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (12)

Processvia Protein(s)Taxonomy
protein bindingSodium/hydrogen exchanger 1Homo sapiens (human)
calmodulin bindingSodium/hydrogen exchanger 1Homo sapiens (human)
phospholipid bindingSodium/hydrogen exchanger 1Homo sapiens (human)
phosphatidylinositol-4,5-bisphosphate bindingSodium/hydrogen exchanger 1Homo sapiens (human)
sodium:proton antiporter activitySodium/hydrogen exchanger 1Homo sapiens (human)
protein phosphatase 2B bindingSodium/hydrogen exchanger 1Homo sapiens (human)
protein-macromolecule adaptor activitySodium/hydrogen exchanger 1Homo sapiens (human)
identical protein bindingSodium/hydrogen exchanger 1Homo sapiens (human)
calcium-dependent protein bindingSodium/hydrogen exchanger 1Homo sapiens (human)
molecular adaptor activitySodium/hydrogen exchanger 1Homo sapiens (human)
sodium:proton antiporter activity involved in regulation of cardiac muscle cell membrane potentialSodium/hydrogen exchanger 1Homo sapiens (human)
potassium:proton antiporter activitySodium/hydrogen exchanger 1Homo sapiens (human)
sodium:proton antiporter activitySodium/hydrogen exchanger 2Homo sapiens (human)
potassium:proton antiporter activitySodium/hydrogen exchanger 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (16)

Processvia Protein(s)Taxonomy
nucleoplasmSodium/hydrogen exchanger 1Homo sapiens (human)
cytoplasmSodium/hydrogen exchanger 1Homo sapiens (human)
mitochondrionSodium/hydrogen exchanger 1Homo sapiens (human)
plasma membraneSodium/hydrogen exchanger 1Homo sapiens (human)
focal adhesionSodium/hydrogen exchanger 1Homo sapiens (human)
cell surfaceSodium/hydrogen exchanger 1Homo sapiens (human)
intercalated discSodium/hydrogen exchanger 1Homo sapiens (human)
membraneSodium/hydrogen exchanger 1Homo sapiens (human)
basolateral plasma membraneSodium/hydrogen exchanger 1Homo sapiens (human)
apical plasma membraneSodium/hydrogen exchanger 1Homo sapiens (human)
lamellipodiumSodium/hydrogen exchanger 1Homo sapiens (human)
T-tubuleSodium/hydrogen exchanger 1Homo sapiens (human)
membrane raftSodium/hydrogen exchanger 1Homo sapiens (human)
perinuclear region of cytoplasmSodium/hydrogen exchanger 1Homo sapiens (human)
extracellular exosomeSodium/hydrogen exchanger 1Homo sapiens (human)
cation-transporting ATPase complexSodium/hydrogen exchanger 1Homo sapiens (human)
plasma membraneSodium/hydrogen exchanger 1Homo sapiens (human)
plasma membraneSodium/hydrogen exchanger 2Homo sapiens (human)
membraneSodium/hydrogen exchanger 2Homo sapiens (human)
apical plasma membraneSodium/hydrogen exchanger 2Homo sapiens (human)
plasma membraneSodium/hydrogen exchanger 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (46)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID12016Concentration in the plasma after intravenous administration of 1 mg/kg in rat2001Bioorganic & medicinal chemistry letters, Mar-26, Volume: 11, Issue:6
Discovery of zoniporide: a potent and selective sodium-hydrogen exchanger type 1 (NHE-1) inhibitor with high aqueous solubility.
AID731933Fraction unbound in human plasma2013ACS medicinal chemistry letters, Jan-10, Volume: 4, Issue:1
Discovery of the Highly Potent PI3K/mTOR Dual Inhibitor PF-04979064 through Structure-Based Drug Design.
AID1219920Half life in Hartley guinea pig at 2.5 mg/kg, po2012Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3
Deuterium isotope effects on drug pharmacokinetics. I. System-dependent effects of specific deuteration with aldehyde oxidase cleared drugs.
AID731935Half life in human liver S9 fraction in presence of NADPH2013ACS medicinal chemistry letters, Jan-10, Volume: 4, Issue:1
Discovery of the Highly Potent PI3K/mTOR Dual Inhibitor PF-04979064 through Structure-Based Drug Design.
AID232710Selectivity ratio of NHE-1 verus NHE-2 was determined2001Bioorganic & medicinal chemistry letters, Mar-26, Volume: 11, Issue:6
Discovery of zoniporide: a potent and selective sodium-hydrogen exchanger type 1 (NHE-1) inhibitor with high aqueous solubility.
AID1219908AUC in Hartley guinea pig at 1 mg/kg, iv2012Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3
Deuterium isotope effects on drug pharmacokinetics. I. System-dependent effects of specific deuteration with aldehyde oxidase cleared drugs.
AID1215693Drug metabolism in human liver S9 fraction assessed as aldehyde oxidase-mediated 2-oxo-metabolite formation at 10 uM by spectrometry2012Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8
Effect of structural variation on aldehyde oxidase-catalyzed oxidation of zoniporide.
AID731931Plasma clearance in iv dosed human2013ACS medicinal chemistry letters, Jan-10, Volume: 4, Issue:1
Discovery of the Highly Potent PI3K/mTOR Dual Inhibitor PF-04979064 through Structure-Based Drug Design.
AID701663Volume of distribution at steady state in jugular and femoral vein precannulated Sprague-Dawley rat at 1 mg/kg, iv by LC/MS/MS analysis2012Journal of medicinal chemistry, Aug-23, Volume: 55, Issue:16
Identification of a potent sodium hydrogen exchanger isoform 1 (NHE1) inhibitor with a suitable profile for chronic dosing and demonstrated cardioprotective effects in a preclinical model of myocardial infarction in the rat.
AID12100Half life after intravenous administration of 1 mg/kg in rat2001Bioorganic & medicinal chemistry letters, Mar-26, Volume: 11, Issue:6
Discovery of zoniporide: a potent and selective sodium-hydrogen exchanger type 1 (NHE-1) inhibitor with high aqueous solubility.
AID731932Ratio of fraction unbound in blood to fraction unbound in plasma in human2013ACS medicinal chemistry letters, Jan-10, Volume: 4, Issue:1
Discovery of the Highly Potent PI3K/mTOR Dual Inhibitor PF-04979064 through Structure-Based Drug Design.
AID1525699Substrate activity at aldehyde oxidase in rat liver cytosol assessed as enzyme-mediated drug uptake at 1 uM2019Journal of medicinal chemistry, 12-26, Volume: 62, Issue:24
Metabolism by Aldehyde Oxidase: Drug Design and Complementary Approaches to Challenges in Drug Discovery.
AID1215671Drug metabolism in pooled human hepatocytes assessed as aldehyde oxidase-mediated drug metabolism at 10 uM up to 120 mins by HPLC analysis in presence of 25 uM of hydralazine2012Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 40, Issue:7
Hydralazine as a selective probe inactivator of aldehyde oxidase in human hepatocytes: estimation of the contribution of aldehyde oxidase to metabolic clearance.
AID8327Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in dog2001Bioorganic & medicinal chemistry letters, Mar-26, Volume: 11, Issue:6
Discovery of zoniporide: a potent and selective sodium-hydrogen exchanger type 1 (NHE-1) inhibitor with high aqueous solubility.
AID11227Plasma clearance after intravenous administration of 1 mg/kg in rat2001Bioorganic & medicinal chemistry letters, Mar-26, Volume: 11, Issue:6
Discovery of zoniporide: a potent and selective sodium-hydrogen exchanger type 1 (NHE-1) inhibitor with high aqueous solubility.
AID1219922Cmax in Sprague-Dawley rat at 2.5 mg/kg, po2012Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3
Deuterium isotope effects on drug pharmacokinetics. I. System-dependent effects of specific deuteration with aldehyde oxidase cleared drugs.
AID1219923Half life in Sprague-Dawley rat at 2.5 mg/kg, po2012Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3
Deuterium isotope effects on drug pharmacokinetics. I. System-dependent effects of specific deuteration with aldehyde oxidase cleared drugs.
AID143808In vitro concentration of compound required to inhibit NHE-2 mediated intracellular maximal pH recovery by 50%2001Bioorganic & medicinal chemistry letters, Mar-26, Volume: 11, Issue:6
Discovery of zoniporide: a potent and selective sodium-hydrogen exchanger type 1 (NHE-1) inhibitor with high aqueous solubility.
AID1525700Substrate activity at aldehyde oxidase in guinea pig liver cytosol assessed as enzyme-mediated drug uptake at 1 uM2019Journal of medicinal chemistry, 12-26, Volume: 62, Issue:24
Metabolism by Aldehyde Oxidase: Drug Design and Complementary Approaches to Challenges in Drug Discovery.
AID9545Plasma protein binding was determined after intravenous administration of 1 mg/kg in dog2001Bioorganic & medicinal chemistry letters, Mar-26, Volume: 11, Issue:6
Discovery of zoniporide: a potent and selective sodium-hydrogen exchanger type 1 (NHE-1) inhibitor with high aqueous solubility.
AID1215672Drug metabolism in pooled human hepatocytes assessed as aldehyde oxidase-mediated drug metabolism at 10 uM up to 120 mins by HPLC analysis in presence of 50 uM of hydralazine2012Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 40, Issue:7
Hydralazine as a selective probe inactivator of aldehyde oxidase in human hepatocytes: estimation of the contribution of aldehyde oxidase to metabolic clearance.
AID701662Oral bioavailability in jugular and femoral vein precannulated Sprague-Dawley rat plasma at 5 mg/kg by LC/MS/MS analysis2012Journal of medicinal chemistry, Aug-23, Volume: 55, Issue:16
Identification of a potent sodium hydrogen exchanger isoform 1 (NHE1) inhibitor with a suitable profile for chronic dosing and demonstrated cardioprotective effects in a preclinical model of myocardial infarction in the rat.
AID701665Clearance in jugular and femoral vein precannulated Sprague-Dawley rat at 1 mg/kg, iv by LC/MS/MS analysis relative to hepatic blood flow2012Journal of medicinal chemistry, Aug-23, Volume: 55, Issue:16
Identification of a potent sodium hydrogen exchanger isoform 1 (NHE1) inhibitor with a suitable profile for chronic dosing and demonstrated cardioprotective effects in a preclinical model of myocardial infarction in the rat.
AID11116Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in rat2001Bioorganic & medicinal chemistry letters, Mar-26, Volume: 11, Issue:6
Discovery of zoniporide: a potent and selective sodium-hydrogen exchanger type 1 (NHE-1) inhibitor with high aqueous solubility.
AID1219921AUC in Sprague-Dawley rat at 2.5 mg/kg, po2012Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3
Deuterium isotope effects on drug pharmacokinetics. I. System-dependent effects of specific deuteration with aldehyde oxidase cleared drugs.
AID1219919Cmax in Hartley guinea pig at 2.5 mg/kg, po2012Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3
Deuterium isotope effects on drug pharmacokinetics. I. System-dependent effects of specific deuteration with aldehyde oxidase cleared drugs.
AID9905Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in dog2001Bioorganic & medicinal chemistry letters, Mar-26, Volume: 11, Issue:6
Discovery of zoniporide: a potent and selective sodium-hydrogen exchanger type 1 (NHE-1) inhibitor with high aqueous solubility.
AID143806In vitro concentration required to inhibit NHE-1 mediated intracellular maximal pH recovery by 50%2001Bioorganic & medicinal chemistry letters, Mar-26, Volume: 11, Issue:6
Discovery of zoniporide: a potent and selective sodium-hydrogen exchanger type 1 (NHE-1) inhibitor with high aqueous solubility.
AID9105Concentration in the plasma after intravenous administration of 1 mg/kg in dog2001Bioorganic & medicinal chemistry letters, Mar-26, Volume: 11, Issue:6
Discovery of zoniporide: a potent and selective sodium-hydrogen exchanger type 1 (NHE-1) inhibitor with high aqueous solubility.
AID1525698Substrate activity at aldehyde oxidase in human liver cytosol assessed as enzyme-mediated drug uptake at 1 uM2019Journal of medicinal chemistry, 12-26, Volume: 62, Issue:24
Metabolism by Aldehyde Oxidase: Drug Design and Complementary Approaches to Challenges in Drug Discovery.
AID701664Mean resident time in jugular and femoral vein precannulated Sprague-Dawley rat at 1 mg/kg, iv by LC/MS/MS analysis2012Journal of medicinal chemistry, Aug-23, Volume: 55, Issue:16
Identification of a potent sodium hydrogen exchanger isoform 1 (NHE1) inhibitor with a suitable profile for chronic dosing and demonstrated cardioprotective effects in a preclinical model of myocardial infarction in the rat.
AID12354Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in rat2001Bioorganic & medicinal chemistry letters, Mar-26, Volume: 11, Issue:6
Discovery of zoniporide: a potent and selective sodium-hydrogen exchanger type 1 (NHE-1) inhibitor with high aqueous solubility.
AID1219910AUC in Sprague-Dawley rat at 1 mg/kg, iv2012Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3
Deuterium isotope effects on drug pharmacokinetics. I. System-dependent effects of specific deuteration with aldehyde oxidase cleared drugs.
AID8731Plasma clearance after intravenous administration of 1 mg/kg in dog2001Bioorganic & medicinal chemistry letters, Mar-26, Volume: 11, Issue:6
Discovery of zoniporide: a potent and selective sodium-hydrogen exchanger type 1 (NHE-1) inhibitor with high aqueous solubility.
AID10093Half life after intravenous administration of 1 mg/kg in dog2001Bioorganic & medicinal chemistry letters, Mar-26, Volume: 11, Issue:6
Discovery of zoniporide: a potent and selective sodium-hydrogen exchanger type 1 (NHE-1) inhibitor with high aqueous solubility.
AID1219918AUC in Hartley guinea pig at 2.5 mg/kg, po2012Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3
Deuterium isotope effects on drug pharmacokinetics. I. System-dependent effects of specific deuteration with aldehyde oxidase cleared drugs.
AID1219911Half life in Sprague-Dawley rat at 1 mg/kg, iv2012Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3
Deuterium isotope effects on drug pharmacokinetics. I. System-dependent effects of specific deuteration with aldehyde oxidase cleared drugs.
AID1525701Substrate activity at aldehyde oxidase in human hepatocytes assessed as enzyme-mediated drug uptake at 1 uM2019Journal of medicinal chemistry, 12-26, Volume: 62, Issue:24
Metabolism by Aldehyde Oxidase: Drug Design and Complementary Approaches to Challenges in Drug Discovery.
AID1219909Half life in Hartley guinea pig at 1 mg/kg, iv2012Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3
Deuterium isotope effects on drug pharmacokinetics. I. System-dependent effects of specific deuteration with aldehyde oxidase cleared drugs.
AID1215690Half life in human liver S9 fraction assessed as aldehyde oxidase-mediated 2-oxo-metabolite formation at 1 uM by spectrometry2012Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8
Effect of structural variation on aldehyde oxidase-catalyzed oxidation of zoniporide.
AID13462Plasma protein binding was determined after intravenous administration of 1 mg/kg in rat2001Bioorganic & medicinal chemistry letters, Mar-26, Volume: 11, Issue:6
Discovery of zoniporide: a potent and selective sodium-hydrogen exchanger type 1 (NHE-1) inhibitor with high aqueous solubility.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (45)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's16 (35.56)29.6817
2010's26 (57.78)24.3611
2020's3 (6.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 22.43

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index22.43 (24.57)
Research Supply Index3.87 (2.92)
Research Growth Index4.66 (4.65)
Search Engine Demand Index23.28 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (22.43)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (4.44%)5.53%
Reviews2 (4.44%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other41 (91.11%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]